Literature DB >> 12395367

Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers.

Nelson G Ordóñez1.   

Abstract

Numerous new immunohistochemical markers that can be used in the diagnosis of mesothelioma have recently become available. As a result, new panels of antibodies that could be useful for distinguishing between epithelioid mesotheliomas and adenocarcinomas have been proposed. However, great differences of opinion exist regarding the individual value of some of these markers, especially when compared with those whose value has already been established. This article provides a critical review of the currently available information on those markers that could be useful in the diagnosis of epithelioid mesotheliomas or whose utility remains controversial. A practical approach to the diagnosis of these tumors is also provided. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12395367     DOI: 10.1053/hupa.2002.128248

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  Diagnosis and prognosis of malignant mesothelioma of the tunica vaginalis testis.

Authors:  Bo Hai; Yu Yang; Yajun Xiao; Bing Li; Chaohui Chen
Journal:  Can Urol Assoc J       Date:  2011-09-08       Impact factor: 1.862

2.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

3.  Localised pleural malignant mesothelioma. Report of two cases simulating pulmonary carcinoma and review of the literature.

Authors:  Sofia Asioli; Giulia Dal Piaz; Stefania Damiani
Journal:  Virchows Arch       Date:  2004-06-30       Impact factor: 4.064

4.  Localized malignant mesothelioma in the middle mediastinum: report of a case.

Authors:  Shintaro Akamoto; Yasuhiko Ono; Kazumi Ota; Norikazu Suzaki; Akinori Sasaki; Yoshihiro Matsuo; Kazuhiko Hayashi
Journal:  Surg Today       Date:  2008-07-09       Impact factor: 2.549

5.  Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions.

Authors:  Fabio Facchetti; Silvia Lonardi; Francesca Gentili; Luisa Bercich; Marcella Falchetti; Regina Tardanico; Carla Baronchelli; Laura Lucini; Alessandro Santin; Bruno Murer
Journal:  Virchows Arch       Date:  2007-07-03       Impact factor: 4.064

6.  Immunohistochemical characterization of mesothelioma in 6 large felids.

Authors:  Sarah E Coe; Michael M Garner; Matti Kiupel
Journal:  J Vet Diagn Invest       Date:  2021-05-13       Impact factor: 1.279

7.  Specific expression of human intelectin-1 in malignant pleural mesothelioma and gastrointestinal goblet cells.

Authors:  Kota Washimi; Tomoyuki Yokose; Makiko Yamashita; Taihei Kageyama; Katsuo Suzuki; Mitsuyo Yoshihara; Yohei Miyagi; Hiroyuki Hayashi; Shoutaro Tsuji
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

8.  Pleural mesothelioma in a nine-month-old dog.

Authors:  Sevil Atalay Vural; Zafer Ozyildiz; Sule Yurdagul Ozsoy
Journal:  Ir Vet J       Date:  2007-01-01       Impact factor: 2.146

9.  Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis.

Authors:  Li-Ming Wang; Zhen-Wang Shi; Ji-Ling Wang; Zhi Lv; Fang-Bin Du; Qing-Bin Yang; Yong Wang
Journal:  Oncotarget       Date:  2017-08-17

10.  Establishment of anti-mesothelioma monoclonal antibodies.

Authors:  Natsuko Mizutani; Masaaki Abe; Shuji Matsuoka; Kazunori Kajino; Midori Wakiya; Naomi Ohtsuji; Ryo Hatano; Chikao Morimoto; Okio Hino
Journal:  BMC Res Notes       Date:  2016-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.